Analysts See Higher Success Chances For Cytokinetics’ Heart Disease Candidate After Positive Phase 2 Data
Today, Cytokinetics Incorporated (NASDAQ: CYTK) reported positive REDWOOD-HCM Phase 2 data showing CK-274 treatment for ten weeks
Amgen’s deCODE Subsidiary Highlights New Paper Published In Nature Genetics On Inheritance, Fetal Growth
In a paper published in Nature genetics today, Scientists from deCODE genetics, a fully owned subsidiary of Amgen, report sequence variants that associate with birth weight and demonstrate how these variants affect birth
Where Amgen Stands With Analysts
Within the last quarter, Amgen (NASDAQ:AMGN) has observed the following analyst ratings:
Last 30 Days
1 Month Ago
2 Months Ago
Morgan Stanley Maintains Overweight on Amgen, Raises Price Target to $280
Morgan Stanley analyst Matthew Harrison maintains Amgen (NASDAQ:AMGN) with a Overweight and raises the price target from $278 to $280.
FDA Rebukes Amgen Over Misleading Branding Of Neulasta
The FDA has issued an untitled letter to Amgen Inc (NASDAQ:AMGN) for the misbranding of its blockbuster bone marrow stimulant, Neulasta (pegfilgrastim)…
The Daily Biotech Pulse: Lilly, Morphic’s Positive Data At ECCO, Humanigen’s COVID Treatment Gets Expedited Review In UK, TransCode IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 8)
BeiGene-Amgen’s Kyprolis Gets Approval In China For Pre-Treated Multiple Myeloma Patients
The China National Medical Products Administration (NMPA) has conditionally approved Kyprolis (carfilzomib) for relapsed or refractory (R/R) multiple myeloma. The…
The Daily Biotech Pulse: Priority Review For Amgen’s Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 7)
How Does Amgen’s Debt Look?
Over the past three months, shares of Amgen (NASDAQ:AMGN) moved lower by nan%. Before having a look at the importance of debt, let us look at how much debt Amgen has.
Amgen – AstraZeneca’s Asthma Candidate Under Priority Review With FDA
The FDA has accepted for review Amgen Inc’s (NASDAQ:AMGN) marketing application seeking approval for tezepelumab to treat asthma. Amgen is developing…